1-Propan-2-ylcyclopentane-1-carbonitrile | 49826-27-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Propan-2-ylcyclopentane-1-carbonitrile
• CAS: 49826-27-9
• 化学式: C₉H₁₅N
• 分子量: 137.225
• InChiKey: WCWBODISKNBLGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异戊腈 在 lithium diethylamide 作用下， 以 六甲基磷酰三胺 为溶剂， 生成 1-Propan-2-ylcyclopentane-1-carbonitrile
  参考文献：
  名称：

  新丁腈

  摘要：

  HMPT中的二乙氨基锂已用于制备和环化ω-卤代腈。环丁烷衍生物很容易从δ-氯腈中以高收率获得。

  DOI：

  10.1016/s0022-328x(00)86576-6

文献信息

• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Charrier Jean-Damien

  公开号：US20120027874A1

  公开（公告）日：2012-02-02

  The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

  本发明涉及吡嗪和吡啶化合物，其作为ATR蛋白激酶的抑制剂具有用途。本发明还涉及包含本发明化合物的药学上可接受的组合物；使用本发明化合物治疗各种疾病、疾患和病况的方法；制备本发明化合物的过程；用于制备本发明化合物的中间体；以及在体外应用中使用化合物的方法，例如研究生物和病理现象中的激酶、介导这些激酶的细胞内信号转导途径的研究和新的激酶抑制剂的比较评估等。本发明的化合物具有公式I：其中变量如本文所定义。
• Novel Phtalazinone Derivatives and Manufacturing Process Thereof
  申请人：ILDONG PHARM CO., LTD.

  公开号：US20160222003A1

  公开（公告）日：2016-08-04

  The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

  本发明涉及邻苯二酮衍生物，包括制备邻苯二酮衍生物的药物组合物。本发明特别提供了一种用于抑制Poly(ADP-核糖)聚合酶酶活性的邻苯二酮衍生物药物组合物。
• Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
  申请人：Denali Therapeutics Inc.

  公开号：US10709692B2

  公开（公告）日：2020-07-14

  The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

  本公开总体上涉及预防或阻止细胞死亡和/或炎症的方法和组合物。
• COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS
  申请人：Repare Therapeutics Inc.

  公开号：US20210277002A1

  公开（公告）日：2021-09-09

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
• US9630956B2
  申请人：——

  公开号：US9630956B2

  公开（公告）日：2017-04-25